An American Cancer Society Clinician Scientist Development Grant (CSDG) has been awarded to PC3I Faculty Allison Barz Leahy, MD, MSCE. The CSDG provides five years of funding support to junior faculty trained primarily as clinicians who want to maintain clinical practice and conduct cancer research.
Dr. Barz Leahy’s work centers on the use of patient-reported outcome (PRO) measures for symptom monitoring in pediatric cancer patients, with a focus in chimeric antigen receptor (CAR) T cell therapy, a type of treatment in which a patient’s own T cells are altered to attack cancer cells. Through this funding, she will develop novel early warning systems that leverage PROs to inform meaningful and actionable clinical outcomes in pediatric CAR T cell therapy.
In other populations, PROs have been used for toxicity monitoring and have done so more effectively than traditional laboratory measures, but haven’t been assessed to the same extent in pediatric oncology populations. In this pioneering study, PROs collected from pediatric oncology patients and their caregivers will be combined with traditional clinical data to develop advanced predictive models to identify patients most at risk for bad outcomes, such as life-threatening side effects, the premature loss of CAR T cells, or relapse following treatment. These models will allow clinicians to anticipate and mitigate catastrophic events in a particularly high-risk population and improve outcomes overall for children with cancer.
A $3.5 million grant from the National Cancer Institute (NCI) will help clinicians provide better care to women with cervical cancer in the nation of Botswana.
Through the Innovation Accelerator, the Cancer Service Line & PC3I invite applications for initiatives that create and test innovative solutions to address challenges in cancer care access.
PC3I is pleased to share our 2021-2022 Impact Report, which shares highlights from our work over the past year to create, test, and scale solutions to some of the most intractable problems in cancer care delivery.